ArticleFrontiers in pharmacology2026
APMCG-1: a mountain-cultivated ginseng-derived glycopeptide alleviates cerebral ischemic injury by resisting oxidative stress, ferroptosis and inflammation via the Nrf2 signaling pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: APMCG-1 is a glycopeptide derived from the mountain-cultivated ginseng C. A. Mey (APMCG-1), and recent studies have demonstrated its neuroprotective effects. Concurrently, ferroptosis plays an indispensable role in the pathogenesis of ischemic stroke. Investigate the neuroprotective effects of APMCG-1 in mitigating cortical brain injury and neurological dysfunction by suppressing oxidative stress, ferroptosis, and inflammation via the Nrf2 pathway. Methods: Rats underwent middle cerebral artery occlusion (MCAO) model. APMCG-1 (20 mg/kg and 40 mg/kg, gavage, 14 days). CoCl Results: APMCG-1 inhibited oxidative stress, ferroptosis, and inflammation, protecting against cortical injury and neurological dysfunction in MCAO rats, as well as safeguarding cells under OGD/R conditions. These effects were abolished upon Nrf2 inhibition by ML385, indicating that APMCG-1's neuroprotective actions might depend on Nrf2 signaling. Conclusion: APMCG-1 could mitigate cerebral ischemia-reperfusion injury by inhibiting ferroptosis through the Nrf2 pathway, exerting antioxidant effects, and suppressing inflammation, thereby establishing a foundation for potential therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.